Table 3.
Within admission and baseline-adjusted between admission post- to pre-intervention geometric mean outcome measure ratios
| Outcome measure | Protocol | Estimate ratio of GMs (RGMs) | 95% CI | P-value |
|---|---|---|---|---|
| FMD | EU | 1.07 | 0.90, 1.26 | 0.425 (0.850) |
| AH | 1.34 | 1.11, 1.62 | 0.004 (0.008) | |
| RGM AH: RGM EUa | 1.15 | 0.93, 1.42 | 0.178 (0.357) | |
| PIFV | EU | 1.03 | 0.90, 1.18 | 0.678 (1.000) |
| AH | 1.01 | 0.87, 1.18 | 0.907 (1.000) | |
| RGM AH: RGM EUa | 1.03 | 0.93, 1.15 | 0.470 (0.939) | |
| cfPWV | EU | 0.99 | 0.94, 1.04 | 0.635 (1.000) |
| AH | 0.99 | 0.94, 1.05 | 0.830 (1.000) | |
| RGM AH: RGM EUa | 1.00 | 0.92, 1.09 | 0.971 (1.000) | |
| Skeletal MBV | EU | 1.10 | 0.92, 1.32 | 0.273 (0.545) |
| AH | 1.68 | 1.37, 2.06 | <0.001 (<0.001) | |
| RGM AH: RGM EUa | 1.50 | 1.15, 1.95 | 0.008 (0.016) | |
| Skeletal MFV | EU | 1.19 | 0.95, 1.48 | 0.124 (0.247) |
| AH | 1.39 | 1.08, 1.79 | 0.012 (0.024) | |
| RGM AH: RGM EUa | 1.13 | 0.89, 1.44 | 0.274 (0.549) | |
| Skeletal MBF | EU | 1.31 | 0.89, 1.93 | 0.162 (0.324) |
| AH | 2.34 | 1.51, 3.63 | 0.001 (0.001) | |
| RGM AH: RGM EUa | 1.68 | 1.06, 2.64 | 0.031 (0.062) | |
| Cardiac MBV | EU | 1.08 | 0.91, 1.29 | 0.356 (0.712) |
| AH | 1.34 | 1.07, 1.67 | 0.014(0.027) | |
| RGM AH: RGM EUa | 1.14 | 0.91, 1.41 | 0.211 (0.423) | |
| Cardiac MFV | EU | 1.16 | 0.93, 1.45 | 0.181 (0.362) |
| AH | 0.89 | 0.67, 1.18 | 0.415 (0.830) | |
| RGM AH: RGM EUa | 0.70 | 0.55, 0.88 | 0.007 (0.014) | |
| Cardiac MBF | EU | 1.25 | 0.94, 1.67 | 0.113 (0.226) |
| AH | 1.24 | 0.86, 1.78 | 0.235 (0.469) | |
| RGM AH: RGM EUa | 0.79 | 0.57, 1.10 | 0.137 (0.274) |
a
Baseline corrected comparison (Bonferroni-adjusted P-value). AH, acute hyperglycaemia; cfPWV, carotid femoral pulse wave velocity; CI, confidence interval; EU, euglycaemia; FMD, flow-mediated dilatation; GM, geometric mean; MBF, microvascular blood flow; MBV, microvascular blood volume; MFV, microvascular flow velocity; RGM, ratio of geometric mean; PIFV, post-ischaemic flow velocity.